What Aga Medical Holdings does

Aga Medical Holdings, founded in 2005 and headquartered in Plymouth, Minnesota, is a medical device entity that was originally public under NASDAQ ticker AGAM before being acquired and delisted as part of its integration into Abbott's Cardiovascular division (via St. Jude Medical). The amplatzer.com corporate web property persists as a legacy reference, and the entity now operates within Abbott's Cardiac Rhythm Management franchise, which markets a comprehensive portfolio of implantable and connected cardiac devices to electrophysiologists, cardiologists, and allied health professionals globally. John R. Barr is identified as President and Chief Executive Officer.

The product portfolio spans eight core device categories: leadless pacemakers (AVEIR™ DR, marketed as the world's first dual chamber DDD(R) leadless system with upgradeable single-to-dual chamber pathway), MRI-conditional transvenous pacemakers (Assurity MRI™), implantable cardioverter defibrillators (Entrant™ and Gallant™) featuring VF Therapy Assurance and DeFT Response™ technology, insertable cardiac monitors (Assert-IQ™) with Bluetooth connectivity, cardiac resynchronization therapy defibrillators (Gallant™ HF CRT-D) with SyncAV™ Plus and MultiPoint™ pacing, delivery catheters (CPS Locator™ 3D), pacing leads including the UltiPace™ first FDA-approved stylet-driven lead for left bundle branch area pacing, and the Merlin.net™ Patient Care Network remote monitoring and programming platform. The portfolio is described as algorithm-rich, with embedded detection and therapy optimization logic across multiple device categories.

The business model is hardware sales of capital-intensive Class III implantable medical devices sold through a direct field sales force to healthcare systems, hospitals, and electrophysiology clinics. Pricing is quote-based and contract-driven, varying by healthcare system, geography, and payer coverage, and is not publicly disclosed. Geographic reach is global, with country-specific operations in the United States, Australia, Germany, France, and Japan. Marketing is layered: direct representative engagement plus content marketing through the Abbott CRM Blog, an HCP email newsletter, portfolio brochures, and an HCP portal with disease management, education, reimbursement, and technical resources, plus patient and caregiver-facing support content.

Name

Aga Medical Holdings

Legal name

Aga Medical Holdings

Website

https://amplatzer.com

Company type

Private

Founded year

2005

Operating status

Unknown

Short description

Aga Medical Holdings, now integrated into Abbott's Cardiac Rhythm Management division, manufactures and markets a global portfolio of implantable cardiac devices — including leadless pacemakers, ICDs, CRT devices, insertable cardiac monitors, leads, and remote monitoring connectivity — sold through direct field sales to electrophysiologists and healthcare systems worldwide.

Ownership category

akta.pro rank

Product category

Cardiac Rhythm Management Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

Keywords

• Cardiac rhythm management
• Implantable medical devices
• Pacemaker systems
• Cardiac defibrillators
• Cardiac monitoring devices

Headquarters

HQ city

Plymouth

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Cardiac Rhythm Management Medical Devices: Abbott generates revenue through the sale of implantable cardiac devices including pacemakers, ICDs, CRT devices, insertable cardiac monitors, catheters, and leads. These are capital-intensive medical devices sold to healthcare systems, hospitals, and electrophysiology clinics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Aga Medical Holdings is a medical device company focused on cardiac rhythm management. It develops, manufactures, and sells implantable cardiac devices including leadless and transvenous pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy devices, insertable cardiac monitors, delivery catheters, and pacing leads, together with the Merlin.net remote monitoring network. These products are sold to healthcare systems, hospitals, and electrophysiology clinics treating patients with cardiac arrhythmias and heart failure.

Product overview

Abbott's Cardiac Rhythm Management portfolio is a unified platform of life-changing medical devices spanning multiple product categories that work together to diagnose, treat, and monitor cardiac conditions. The portfolio includes leadless pacemakers (AVEIR™ DR), traditional wireless MRI pacemakers (Assurity MRI™), implantable cardioverter defibrillators (Entrant™ and Gallant™), insertable cardiac monitors (Assert-IQ™), cardiac resynchronization therapy devices (Gallant™ HF CRT-D), remote monitoring connectivity (Merlin.net™ Patient Care Network), delivery catheters (CPS Locator™ 3D), and cardiac leads (UltiPace™). These products offer enhanced connectivity, algorithm-rich therapies, and intelligent monitoring capabilities that provide functional flexibility for physicians managing cardiac patients.

Differentiator

Problem solved

Functional benefit

Products and services

• AVEIR DR Leadless Pacemaker System The world's first dual chamber DDD(R) leadless pacemaker system, offering the option to implant an atrial or ventricular device alone, or both for dual chamber support, with ability to upgrade from single to dual chamber anytime. Targeted at electrophysiologists and cardiologists managing patients requiring bradycardia support.
• Assurity MRI Pacemaker The longest lasting compact wireless MRI pacemaker, providing a full suite of features for the performance physicians demand and the quality care patients deserve. Targeted at physicians needing MRI-conditional transvenous pacing.
• Entrant ICD Implantable cardioverter defibrillator offering enhanced arrhythmia detection with VF Therapy Assurance. Targeted at electrophysiologists treating patients at risk of ventricular tachyarrhythmias.
• Gallant ICD Implantable cardioverter defibrillator with enhanced arrhythmia detection and better therapy management using DeFT Response technology. Targeted at electrophysiologists managing patients with ventricular tachyarrhythmias.
• Assert-IQ Insertable Cardiac Monitor (ICM) The longest lasting Bluetooth-enabled insertable cardiac monitor offering reduced false positives, simplified clinic workflows, and reduced data burden. Targeted at physicians diagnosing and monitoring patients with suspected cardiac arrhythmias.
• Gallant HF CRT-D MR conditional cardiac resynchronization therapy defibrillator offering easier, faster, more effective CRT optimization with SyncAV Plus CRT technology and MultiPoint pacing. Targeted at electrophysiologists and cardiologists treating heart failure patients requiring cardiac resynchronization.
• Merlin.net Patient Care Network (PCN) Remote monitoring and programming network for implantable devices, offering enhanced compliance, clinic efficiency, informed clinical decisions, and positive patient outcomes. Targeted at electrophysiology clinics and hospitals managing patients with implanted cardiac devices.
• CPS Locator 3D Delivery Catheters Single-use percutaneous catheters intended to introduce various types of catheters and pacing or defibrillator leads. Targeted at electrophysiologists performing cardiac device implantation procedures.
• UltiPace Pacing Lead Stylet-driven pacing lead, engineered by Abbott as the first provider of FDA-approved leads for left bundle branch area pacing (LBBAP). Targeted at electrophysiologists performing physiological pacing procedures.

Quantifiable outcome

• Longest lasting compact wireless MRI pacemaker with Assurity MRI™
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Emerging players

• EBR Systems: EBR Systems is developing the WiSE pacing system for wireless cardiac pacing, an emerging leadless alternative that targets CRT patients and competes conceptually with Abbott's leadless pacemaker franchise in the next frontier of pacing.

Direct peers

• Medtronic: Medtronic's Cardiac Rhythm & Heart Failure division is the global leader in pacemakers, ICDs, CRT devices, and insertable cardiac monitors, directly competing with the AVEIR, Assurity, Entrant/Gallant, Assert-IQ, and Gallant HF CRT-D portfolio across every CRM product category.
• Boston Scientific: Boston Scientific's Cardiology division competes directly with the AVEIR leadless pacemakers, Emblem S-ICD, and Resonate/Accolade ICD/CRT-D families, and its Latitude remote monitoring platform parallels Merlin.net as a clinic-side connectivity solution.
• Biotronik: Biotronik is a privately held German specialist in CRM with Edora/Evity pacemakers, Ilivia/Intica ICDs, and the Home Monitoring remote platform; it competes head-to-head with the AVEIR, Assurity, Entrant/Gallant, and Merlin.net families, especially in EMEA.
• MicroPort Scientific (CRM division): MicroPort's CRM business (formed around the LivaNova CRM acquisition and rebranded as MicroPort CRM) markets pacemakers, ICDs, and CRT-Ds that directly overlap with Abbott's CRM portfolio, particularly in European and emerging markets.

Broad incumbents

• GE HealthCare: GE HealthCare provides MUSE cardiology information systems, EKGs, and patient monitoring solutions that are complementary-adjacent to the implantable CRM franchise; it competes for hospital cardiology budget allocation and clinical workflow integration.
• Philips (Cardiac Care): Philips is a broad incumbent in cardiac care with wearable ECG monitors (BioTel/Express 365) and clinical decision support; while not a direct competitor in implantable CRM, it overlaps with Assert-IQ in the cardiac monitoring category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aga Medical Holdings